Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.
Kazmi F. et al, (2025), Cochrane database syst rev, 3
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC. et al, (2025), Nat commun, 16
Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures.
Di Giovannantonio M. et al, (2025), Cell genom, 5
The Impact of Body Mass Index (BMI) on Clinical Outcomes for Patients Receiving Systemic Anti-Cancer Therapies for Advanced Clear Cell Renal Carcinoma.
Greene J. et al, (2025), Cancer control, 32
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.
Javed SR. et al, (2024), Br j cancer
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Spiliopoulou P. et al, (2024), J exp clin cancer res, 43
New role of fat-free mass in cancer risk linked with genetic predisposition.
Harris BHL. et al, (2024), Sci rep, 14
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
Javed SR. et al, (2024), Br j cancer, 130, 467 - 475
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Henriksen PA. et al, (2023), Circulation, 148, 1680 - 1690
Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases.
Pagnamenta AT. et al, (2023), Genome med, 15
Predicting 10-year breast cancer mortality risk in the general female population in England: a model development and validation study.
Clift AK. et al, (2023), Lancet digit health, 5, e571 - e581
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC. et al, (2023), Nat commun, 14
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Macaulay VM. et al, (2023), Br j cancer
Early phase antitumour clinical trials and palliative medicine.
Virani F. et al, (2023), Bmj support palliat care
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Charles Coombes R. et al, (2023), Nat commun, 14
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM. et al, (2023), Cancer cell, 41, 1222 - 1241.e7
Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study.
Clift AK. et al, (2023), Bmj, 381
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?
Lord SR. and Harris AL., (2023), Br j cancer, 128, 958 - 966
Data from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Cheng VWT. et al, (2023)